Properties (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
government agency
|
| gptkbp:aimsTo |
SARS-CoV-2 virus
|
| gptkbp:approves |
COVID-19_treatment
|
| gptkbp:availableIn |
multiple countries
|
| gptkbp:clinicalTrials |
gptkb:New_England_Journal_of_Medicine
Phase 3 |
| gptkbp:composedOf |
casirivimab
imdevimab |
| gptkbp:developedBy |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:hasAuthorityOver |
gptkb:FDA
|
| gptkbp:hasTheme |
pregnant women
elderly patients pediatric patients immunocompromised patients |
| https://www.w3.org/2000/01/rdf-schema#label |
Regen-Cov
|
| gptkbp:isAttendedBy |
healthcare_professionals
|
| gptkbp:isAvailableIn |
hospital pharmacies
outpatient_clinics |
| gptkbp:isConsidered |
combination therapy in some cases
monotherapy in some cases |
| gptkbp:isDedicatedTo |
variants of concern
|
| gptkbp:isEvaluatedBy |
post-exposure prophylaxis
pre-exposure prophylaxis long COVID treatment COVID-19_variants_treatment |
| gptkbp:isNear |
vaccine
cure for COVID-19 |
| gptkbp:isPartOf |
combination therapy
Regeneron's_COVID-19_response |
| gptkbp:isRecognizedFor |
severe COVID-19 cases
|
| gptkbp:isSubjectTo |
clinical guidelines
supply chain management distribution regulations |
| gptkbp:issuedBy |
high-risk patients
subcutaneous injection |
| gptkbp:isSuitableFor |
vaccines
|
| gptkbp:isUsedFor |
inpatient settings
outpatient settings other COVID-19 treatments |
| gptkbp:marketedAs |
REGEN-COV
|
| gptkbp:partOf |
COVID-19 treatment guidelines
|
| gptkbp:presentedBy |
hospitalization rates
death rates |
| gptkbp:requires |
prescription
adverse reactions |
| gptkbp:sideEffect |
fatigue
headache nausea allergic reactions infusion reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
preventing COVID-19 infection
treating mild to moderate COVID-19 |